U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07326371) titled 'Glofitamab Combined With CAR-T Therapy in R/R DLBCL' on Dec. 26, 2025.
Brief Summary: This study is a single-center, open-label, prospective study aimed at evaluating the efficacy and safety of Glofitamab combined with CAR-T therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
DLBCL - Diffuse Large B Cell Lymphoma
Intervention:
DRUG: Glofitamab
Glofitamab IV infusion will be administered as per the schedule specified in the respective arm.
DRUG: Obinutuzumab
Obinutuzumab IV infusion will be administered as per the schedule specified ...